Qi Zhang1, Junxiu Wu2, Xinpeng Chen3, Ming Zhao4, Dahong Zhang1, Feng Gao5. 1. Department of Urology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou 310014, China. 2. Graduate Department, Zhejiang Chinese Medical University, Hangzhou 310053, China. 3. Graduate Department, Bengbu Medical College, Bengbu, 233030, China. 4. Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou 310014, China. 5. Department of Acupuncture & Massage, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
Abstract
OBJECTIVE: This work analyzes the role of versican (VCAN) on bladder cancer (BLCA). Versican (VCAN) is a chondroitin sulfate proteoglycan which is important for tumorigenesis and the development of cancer. However, the expression of VCAN on human bladder cancer (BLCA) has been rarely reported. METHODS: The clinical significance of VCAN in BLCA has been determined by our bioinformatics tools. Then, we performed immunohistochemical staining (IHC) and analyzed the correlation between VCAN expression and clinicopathological features. RESULTS: The bioinformatics results reveal that a high VCAN mRNA level was significantly associated with stage, histological subtype, molecular subtype, and metastasis in BLCA. Furthermore, IHC reveals that expression of VCAN was significantly correlated with the number of tumors, invasion depth, lymph node metastasis, distant metastasis, and histological grade. Kaplan-Meier survival analysis reveals that patients with a high expression of VCAN have poor prognosis than those patients with a low expression of VCAN. According to our result from the bioinformatics database, the mechanism of VCAN in BLCA revealed that VCAN was related to FBN1 and genes of the ECM remodeling pathway (MMP1, MMP2). CONCLUSION: VCAN expression might be included in the process of carcinogenesis and prognosis. Hence, VCAN could be a reliable biomarker of the clinical prognosis on BLCA.
OBJECTIVE: This work analyzes the role of versican (VCAN) on bladder cancer (BLCA). Versican (VCAN) is a chondroitin sulfate proteoglycan which is important for tumorigenesis and the development of cancer. However, the expression of VCAN on human bladder cancer (BLCA) has been rarely reported. METHODS: The clinical significance of VCAN in BLCA has been determined by our bioinformatics tools. Then, we performed immunohistochemical staining (IHC) and analyzed the correlation between VCAN expression and clinicopathological features. RESULTS: The bioinformatics results reveal that a high VCAN mRNA level was significantly associated with stage, histological subtype, molecular subtype, and metastasis in BLCA. Furthermore, IHC reveals that expression of VCAN was significantly correlated with the number of tumors, invasion depth, lymph node metastasis, distant metastasis, and histological grade. Kaplan-Meier survival analysis reveals that patients with a high expression of VCAN have poor prognosis than those patients with a low expression of VCAN. According to our result from the bioinformatics database, the mechanism of VCAN in BLCA revealed that VCAN was related to FBN1 and genes of the ECM remodeling pathway (MMP1, MMP2). CONCLUSION: VCAN expression might be included in the process of carcinogenesis and prognosis. Hence, VCAN could be a reliable biomarker of the clinical prognosis on BLCA.
Authors: Carmela Ricciardelli; John H Brooks; Supaporn Suwiwat; Andrew J Sakko; Keiko Mayne; Wendy A Raymond; Ram Seshadri; Richard G LeBaron; David J Horsfall Journal: Clin Cancer Res Date: 2002-04 Impact factor: 12.531
Authors: Carmela Ricciardelli; Darryl L Russell; Miranda P Ween; Keiko Mayne; Supaporn Suwiwat; Sharon Byers; Villis R Marshall; Wayne D Tilley; David J Horsfall Journal: J Biol Chem Date: 2007-02-09 Impact factor: 5.157
Authors: M Stylianou; S S Skandalis; T A Papadas; N S Mastronikolis; D A Theocharis; N Papageorgakopoulou; D H Vynios Journal: Anticancer Res Date: 2008 Jan-Feb Impact factor: 2.480
Authors: Nabila El Kramani; Nehal M Elsherbiny; Amal M El-Gayar; Mohamed A Ebrahim; Mohammed M H Al-Gayyar Journal: Cytokine Date: 2018-06-01 Impact factor: 3.861
Authors: Carmela Ricciardelli; Andrew J Sakko; Miranda P Ween; Darryl L Russell; David J Horsfall Journal: Cancer Metastasis Rev Date: 2009-06 Impact factor: 9.264
Authors: Hye Won Lee; Mi Ju Kang; Young-Ju Kwon; Sama Abdi Nansa; Eui Hyun Jung; Sung Han Kim; Sang-Jin Lee; Kyung-Chae Jeong; Youngwook Kim; Heesun Cheong; Ho Kyung Seo Journal: Biomedicines Date: 2022-05-18